Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2025-02-27 Report Publication Anno…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
Report Publication Announcement Classification · 99% confidence The document is very short (843 characters) and explicitly functions as a notice. The subject line is "Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis 30.06.2025" (Notice of Half-Year Financial Report for the period 01.01.2025 to 30.06.2025). It provides a link where the report can be found and states the publication date of this notice (27.02.2025). This structure perfectly matches the definition of a Report Publication Announcement (RPA), which announces the availability of a report rather than being the report itself. The report being announced is a half-year report, which would typically be classified as 'IR' (Interim Report), but since this document is only the announcement, RPA is the correct classification based on the 'MENU VS MEAL' rule.
2025-02-27 German
Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc RELEASE' announcing 'preliminary business figures' for the 2024 financial year, including revenue, cash flow, EBIT, and ROCE. This content structure—providing key financial highlights immediately after the period ends, often before the final audit—is characteristic of an Earnings Release (ER). It explicitly states that the final figures and the annual report will be published later on March 31, 2025. Therefore, this is the initial announcement of results, not the comprehensive Annual Report (10-K) or the announcement of the report's publication (RPA). FY 2024
2025-02-26 English
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)
Regulatory Filings Classification · 95% confidence The document is a press release dated January 9, 2025, announcing that Biotest AG has submitted a Biologics License Application (BLA) for its Fibrinogen product to the US Food and Drug Administration (FDA). This announcement concerns a regulatory submission for a new drug/biologic product, which is a significant corporate event related to product development and regulatory milestones. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about a regulatory submission/milestone that doesn't fit perfectly into the financial reporting codes (like 10-K or IR), it falls best under the general 'Regulatory Filings' category (RNS) as a significant corporate news item, or potentially 'LTR' if viewed as a regulatory action, but RNS is the broader category for general regulatory news not covered elsewhere. Given the context of a major regulatory submission announcement, RNS is the most appropriate general classification for significant, non-financial, non-management-change news.
2025-01-10 English
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)
Regulatory Filings Classification · 95% confidence The document is a press release dated January 9, 2025, announcing that Biotest AG has submitted a Biologics License Application (BLA) for its Fibrinogen product to the US Food and Drug Administration (FDA). This announcement concerns a regulatory submission for a new drug/biologic product, which is a significant corporate event related to product development and regulatory milestones. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about a regulatory submission/milestone that doesn't fit perfectly into the financial reporting codes (like 10-K or IR), it falls best under the general 'Regulatory Filings' category (RNS) as a significant corporate news item, or potentially 'LTR' if viewed as a regulatory action, but RNS is the broader category for general regulatory news not covered elsewhere. Given the context of a major regulatory submission announcement, RNS is the most appropriate general classification for significant, non-financial, non-management-change news.
2025-01-09 English
Remunerations Report 2023
Remuneration Information Classification · 99% confidence The document is titled 'Independent Auditor's Assurance Report on Examination of the Remuneration Report pursuant to Section 162 (3) AktG' and contains an 'Opinion' section confirming compliance with disclosure requirements for the remuneration report. The main body of the text is the 'Remuneration Report 2023' itself, detailing the structure, components (fixed, STI, LTI), and performance metrics for the Board of Management's compensation. This content directly relates to executive compensation disclosure, which aligns with the definition of Remuneration Information (DEF 14A). Although it includes an auditor's report, the primary focus and bulk of the document is the detailed remuneration disclosure, making DEF 14A the most specific classification over a general Audit Report (AR) or Regulatory Filing (RNS). The document length is substantial (over 55k characters), confirming it is the report itself, not just an announcement.
2024-11-29 English
Remunerations Report 2023
Remuneration Information Classification · 99% confidence The document is titled 'Independent Auditor's Assurance Report on Examination of the Remuneration Report pursuant to Section 162 (3) AktG' and contains an 'Opinion' section confirming compliance with disclosure requirements for the remuneration report. The main body of the text is the 'Remuneration Report 2023' itself, detailing the structure, components (fixed, STI, LTI), and performance metrics for the Board of Management's compensation. This content directly relates to executive compensation disclosure, which aligns with the definition of Remuneration Information (DEF 14A). Although it includes an auditor's report, the primary focus and bulk of the document is the detailed remuneration disclosure, making DEF 14A the most specific classification over a general Audit Report (AR) or Regulatory Filing (RNS). The document length is substantial (over 55k characters), confirming it is the report itself, not just an announcement.
2024-11-28 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.